84 related articles for article (PubMed ID: 34871363)
1. CAR T-cell therapy in primary central nervous system lymphoma: the clinical experience of the French LOC network.
Alcantara M; Houillier C; Blonski M; Rubio MT; Willems L; Rascalou AW; Le Garff-Tavernier M; Maloum K; Bravetti C; Souchet L; Roos-Weil D; Morel V; Uzunov M; Metz C; Dhib-Charfi M; Nguyen S; Shor N; Psimaras D; Weiss N; Jacque N; Solorzano S; Gauthier N; Le Cann M; Norol F; Soussain C; Choquet S
Blood; 2022 Feb; 139(5):792-796. PubMed ID: 34871363
[No Abstract] [Full Text] [Related]
2. Stereotactic radiotherapy and CART for treatment of secondary CNS lymphoma.
Akingbemi W; Kurtz G; Yegya-Raman N; Plastaras JP; Schuster SJ; Chong EA
Leuk Lymphoma; 2024 Jun; 65(6):860-863. PubMed ID: 38451075
[No Abstract] [Full Text] [Related]
3. Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trial.
Frigault MJ; Dietrich J; Gallagher K; Roschewski M; Jordan JT; Forst D; Plotkin SR; Cook D; Casey KS; Lindell KA; Depinho GD; Katsis K; Elder EL; Leick MB; Choi B; Horick N; Preffer F; Saylor M; McAfee S; O'Donnell PV; Spitzer TR; Dey B; DeFilipp Z; El-Jawahri A; Batchelor TT; Maus MV; Chen YB
Blood; 2022 Apr; 139(15):2306-2315. PubMed ID: 35167655
[TBL] [Abstract][Full Text] [Related]
4. The genomic and transcriptional landscape of primary central nervous system lymphoma.
Radke J; Ishaque N; Koll R; Gu Z; Schumann E; Sieverling L; Uhrig S; Hübschmann D; Toprak UH; López C; Hostench XP; Borgoni S; Juraeva D; Pritsch F; Paramasivam N; Balasubramanian GP; Schlesner M; Sahay S; Weniger M; Pehl D; Radbruch H; Osterloh A; Korfel A; Misch M; Onken J; Faust K; Vajkoczy P; Moskopp D; Wang Y; Jödicke A; Trümper L; Anagnostopoulos I; Lenze D; Küppers R; Hummel M; Schmitt CA; Wiestler OD; Wolf S; Unterberg A; Eils R; Herold-Mende C; Brors B; ; Siebert R; Wiemann S; Heppner FL
Nat Commun; 2022 May; 13(1):2558. PubMed ID: 35538064
[TBL] [Abstract][Full Text] [Related]
5. Toxicity and efficacy of CAR T-cell therapy in primary and secondary CNS lymphoma: a meta-analysis of 128 patients.
Cook MR; Dorris CS; Makambi KH; Luo Y; Munshi PN; Donato M; Rowley S; Saad A; Goy A; Dunleavy K; Ali A
Blood Adv; 2023 Jan; 7(1):32-39. PubMed ID: 36260735
[TBL] [Abstract][Full Text] [Related]
6. Molecular and clinical diversity in primary central nervous system lymphoma.
Hernández-Verdin I; Kirasic E; Wienand K; Mokhtari K; Eimer S; Loiseau H; Rousseau A; Paillassa J; Ahle G; Lerintiu F; Uro-Coste E; Oberic L; Figarella-Branger D; Chinot O; Gauchotte G; Taillandier L; Marolleau JP; Polivka M; Adam C; Ursu R; Schmitt A; Barillot N; Nichelli L; Lozano-Sánchez F; Ibañez-Juliá MJ; Peyre M; Mathon B; Abada Y; Charlotte F; Davi F; Stewart C; de Reyniès A; Choquet S; Soussain C; Houillier C; Chapuy B; Hoang-Xuan K; Alentorn A
Ann Oncol; 2023 Feb; 34(2):186-199. PubMed ID: 36402300
[TBL] [Abstract][Full Text] [Related]
7. Toxicities and Response Rates of Secondary CNS Lymphoma After Adoptive Immunotherapy With CD19-Directed Chimeric Antigen Receptor T Cells.
Karschnia P; Rejeski K; Winkelmann M; Schöberl F; Bücklein VL; Blumenberg V; Schmidt C; Blobner J; von Bergwelt-Baildon M; Tonn JC; Kunz WG; Subklewe M; von Baumgarten L
Neurology; 2022 May; 98(21):884-889. PubMed ID: 35351785
[TBL] [Abstract][Full Text] [Related]
8. Self-regulating CAR-T cells modulate cytokine release syndrome in adoptive T-cell therapy.
Lin MY; Nam E; Shih RM; Shafer A; Bouren A; Ayala Ceja M; Harris C; Khericha M; Vo KH; Kim M; Tseng CH; Chen YY
J Exp Med; 2024 Jun; 221(6):. PubMed ID: 38607370
[TBL] [Abstract][Full Text] [Related]
9. Treatment of secondary CNS lymphoma using CD19-targeted chimeric antigen receptor (CAR) T cells.
Kline K; Luetkens T; Koka R; Kallen ME; Chen W; Ahmad H; Omili D; Iraguha T; Gebru E; Fan X; Miller A; Dishanthan N; Baker JM; Dietze KA; Hankey KG; Yared JA; Hardy NM; Rapoport AP; Dahiya S; Atanackovic D
Cancer Immunol Immunother; 2024 Feb; 73(3):45. PubMed ID: 38349430
[TBL] [Abstract][Full Text] [Related]
10. Chimeric Antigen Receptor-T Cell Therapy for Lymphoma: New Settings and Future Directions.
Benevolo Savelli C; Clerico M; Botto B; Secreto C; Cavallo F; Dellacasa C; Busca A; Bruno B; Freilone R; Cerrano M; Novo M
Cancers (Basel); 2023 Dec; 16(1):. PubMed ID: 38201473
[TBL] [Abstract][Full Text] [Related]
11. Role and application of chemokine CXCL13 in central nervous system lymphoma.
Li C; Zhang L; Jin Q; Jiang H; Wu C
Ann Hematol; 2023 Nov; ():. PubMed ID: 38010409
[TBL] [Abstract][Full Text] [Related]
12. Neurotoxicity of Cancer Immunotherapies Including CAR T Cell Therapy.
Song KW; Scott BJ; Lee EQ
Curr Neurol Neurosci Rep; 2023 Dec; 23(12):827-839. PubMed ID: 37938472
[TBL] [Abstract][Full Text] [Related]
13. Extranodal lymphoma: pathogenesis, diagnosis and treatment.
Yang H; Xun Y; Ke C; Tateishi K; You H
Mol Biomed; 2023 Sep; 4(1):29. PubMed ID: 37718386
[TBL] [Abstract][Full Text] [Related]
14. How I treat secondary CNS involvement by aggressive lymphomas.
Alderuccio JP; Nayak L; Cwynarski K
Blood; 2023 Nov; 142(21):1771-1783. PubMed ID: 37702537
[TBL] [Abstract][Full Text] [Related]
15. Successful treatment by CAR T-cells in multi-refractory mantle cell lymphoma with central nervous system involvement.
Caillet A; Houillier C; Sourdeau E; Gazzano M; Uzunov M; Friser V; Ribeiro M; Nicelli L; Azar N; Baron M; Phina-Ziebin X; Choquet S; Roos-Weil D
Ann Hematol; 2023 Nov; 102(11):3295-3297. PubMed ID: 37580574
[No Abstract] [Full Text] [Related]
16. Neurotoxicity and management of primary and secondary central nervous system lymphoma after adoptive immunotherapy with CD19-directed chimeric antigen receptor T-cells.
Karschnia P; Arrillaga-Romany IC; Eichler A; Forst DA; Gerstner E; Jordan JT; Ly I; Plotkin SR; Wang N; Martinez-Lage M; Winter SF; Tonn JC; Rejeski K; von Baumgarten L; Cahill DP; Nahed BV; Shankar GM; Abramson JS; Barnes JA; El-Jawahri A; Hochberg EP; Johnson PC; Soumerai JD; Takvorian RW; Chen YB; Frigault MJ; Dietrich J
Neuro Oncol; 2023 Dec; 25(12):2239-2249. PubMed ID: 37402650
[TBL] [Abstract][Full Text] [Related]
17. CAR T-cell therapy for central nervous system lymphomas: blood and cerebrospinal fluid biology, and outcomes.
Lacan C; Caron J; Tarantino N; Fouquet B; Cherai M; Parizot C; Morel V; Souchet L; Uzunov M; Gorochov G; Nguyen-Quoc S; Sourdeau E; Vieillard V; Miyara M; Vinit A; Solorzano S; Soussain C; Houillier C; Metz C; Autran B; Litvinova E; Le Garff-Tavernier M; Norol F; Roos-Weil D; Choquet S; Guihot A; Baron M
Haematologica; 2023 Dec; 108(12):3485-3490. PubMed ID: 37345469
[No Abstract] [Full Text] [Related]
18. Primary central nervous system lymphoma.
Ferreri AJM; Calimeri T; Cwynarski K; Dietrich J; Grommes C; Hoang-Xuan K; Hu LS; Illerhaus G; Nayak L; Ponzoni M; Batchelor TT
Nat Rev Dis Primers; 2023 Jun; 9(1):29. PubMed ID: 37322012
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
